Navigation Links
Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
Date:3/13/2008

y alters cellular signaling required for cell survival. RAV12 is highly efficacious in human colon, gastric, and pancreatic tumor xenograft models in vivo and has been found to be well tolerated in repeat dose primate toxicology studies.

About Pancreatic Cancer

Adenocarcinoma of the pancreas is a major unmet medical need and represents the fourth leading cause of cancer death in the US. Approximately 34,000 new cases of pancreatic cancer are reported in the US each year. Five-year survival rates are approximately 1% to 2%. Gemcitabine was approved for use in pancreatic cancer a decade ago, but little advance in treatment outcomes has occurred since.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast and ovarian cancer.

On November 12, 2007, Raven and VaxGen Inc. (OTC: VXGN.PK), a biopharmaceutical company, announced that their respective boards of directors unanimously approved a definitive merger agreement. The merger is expected
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
2. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
7. Inclinix Announces New Patent for Expert System Platform
8. Genzyme Announces Presentation of New Positive Data on Carticel(R)
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
(Date:9/22/2014)... YORK , September 22, 2014 ... Market Report on "Global Market Study on Ophthalmic Devices: ... by 2020," the global ophthalmic devices market was valued at USD ... at a CAGR of 6.5% from 2014 to 2020, ... in 2020. Browse the full Global Market Study ...
(Date:9/22/2014)... -- AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), a ... announced today that they are starting production of the ... is designed for placement inside optical shops and Eye ... there are over 20,000 optical stores in America.  ... first automated kiosk dedicated to cleaning and sanitizing eyeglasses ...
Breaking Medicine Technology:Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2
... MARY, Fla., Jan. 26, 2012   In a pediatric ... caring environment, Middleton Pediatrics is one of the first ... to assess their young patients vision.  This revolutionary vision ... important vision data in one second or less.  ...
... 26, 2012  Aria Diagnostics, a molecular diagnostics company, ... study that examines the accuracy of its non-invasive ... (associated with Down syndrome) and Trisomy 18 (associated ... test, coupled with a proprietary algorithm to assess ...
Cached Medicine Technology:Middleton Pediatrics Now Using Spot to Screen Patients 2Middleton Pediatrics Now Using Spot to Screen Patients 3Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology 2
(Date:9/22/2014)... RI (PRWEB) September 22, 2014 Severe weather can ... of time. That’s why, as part of National Preparedness Month, ... and your family prepare for the unexpected:, , ... well as nonperishable food and one gallon of water per person ... Create an evacuation plan that includes pets so your family ...
(Date:9/22/2014)... / Westchester County, NY (PRWEB) September 22, 2014 ... (NYGPS) has joined the Department of Surgery at the ... named Mount Sinai Doctors New York Group for Plastic ... lower Hudson Valley access to a team of world-renowned ... techniques. Additionally, C. Andrew Salzberg, MD, who led ...
(Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
(Date:9/22/2014)... The report segments the global physiotherapy equipment ... The equipment segment accounted for a lion’s share ... However, the accessories segment is expected to grow ... owing to the rising demand of physiotherapy services ... are the fastest-growing segments in the physiotherapy equipment ...
(Date:9/22/2014)... critical information systems, such as medical records in ... new approach to computer security that authenticates users ... automatically logs them out when they leave or ... terminal. , Dartmouth,s Trustworthy Health and Wellness ... at the IEEE Symposium on Security & ...
Breaking Medicine News(10 mins):Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3
... Patient Satisfaction Scores Through Implementing the RROHC Bundle of ... Feb. 27 -- Hansten Healthcare PLLC , a ... and skill development and improving patient satisfaction scores, today ... company as faculty and RROHC Master Coach. , ...
... LAS VEGAS, Feb. 27 Orthopaedic surgeon David ... Specialty Societies (BOS), of the American Academy of Orthopaedic ... Meeting. Dr. Polly will also sit on the Academy,s ... in the Department of Orthopaedic Surgery at the University ...
... United States have used yeast and mammalian cells to ... Parkinson,s disease. , Yeasts are single cell organisms, ... that of cells found in animals and humans. Yeasts ... and offer the ability to screen or test thousands ...
... Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) ... procedure pursuant to Law 223/1991 concerning its Bresso, Italy, ... total of 62 employees. Within 75 days of ... Trade Unions, will review solutions that may reduce the ...
... shares poetry author,s two-year period of severe depressionBROOKLYN, N.Y., ... Arthur F. Temple kept a journal, in which the ... had become intolerable, and the result is this fascinating ... ).In nearly 100 poems, Temple shares his heartfelt feelings ...
... Driven by Demand for Branded Products- Adjusted Diluted EPS ... 2009 Adjusted EPS Guidance Range of $2.59 - $2.67CHADDS ... ENDP ) today reported double-digit percentage growth in ... the fourth quarter and full year ended December 31, ...
Cached Medicine News:Health News:Relationship and Results Oriented Healthcare Announces New Faculty With Impressive Patient Satisfaction Scores 2Health News:David W. Polly Jr., MD, Elected Secretary of Academy Board of Specialty Societies 2Health News:How yeast is helping us to understand Parkinson's Disease 2Health News:How yeast is helping us to understand Parkinson's Disease 3Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 2Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 3Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 4Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 5Health News:Journey into the Dark Recesses of the Subconscious Mind 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 3Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 4Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 5Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 6Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 7Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 8Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 9Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 10Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 11Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 12Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 13Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 14
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
... concave seats and large backrests with lumbar ... armrests, and casters and glides. • Choose ... a variety of environments including: industry, education, ... and office. • With reinforced nylon base ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
Medicine Products: